ERBB2 and neoplasm: Significant discordances between ER, PR, and/or HER2 status among enriched pooled CTCs and corresponding primary tumors have been observed in patients with primary and metastatic breast cancers [41]–[45], and may lead to clinical trials testing CTC biomarkers rather than strict reliance on primary tumor biomarkers for the selection of targeted therapies.